BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Nucynta tapentadol ER regulatory update

FDA approved an NDA from Johnson & Johnson for twice-daily Nucynta tapentadol extended release (ER) to manage moderate to severe acute pain in adults. FDA approved the drug with a REMS about the risk of misuse, abuse, overdose and addiction....

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >